The laboratory operator Synlab is to disappear from the stock exchange three years after its initial listing.

The financial investor Cinven, which controls the majority of Synlab, announced a takeover bid for the outstanding shares on Friday. Synlab will then be delisted. Cinven currently holds around 86 percent of the shares in Synlab via the holding company Ephios.

Cinven listed Synlab on the stock market in spring 2021 at a valuation of 5.9 billion euros including debt. However, the Munich-based company proved to be a flop on the stock market after the end of the coronavirus test boom, which is why Cinven decided to buy it back. Synlab is currently valued at just under 2.4 billion euros.

(Report by Christina Amann, edited by Ralf Banser. If you have any questions, please contact our editorial team at Berlin.Newsroom@thomsonreuters.com (for politics and the economy) or Frankfurt.Newsroom@thomsonreuters.com (for companies and markets)